Department of Liver Surgery, Liver Transplantation Center, West China Hospital of Sichuan University, Chengdu, Sichuan Province, China.
J Cancer Res Clin Oncol. 2021 Feb;147(2):607-618. doi: 10.1007/s00432-020-03364-x. Epub 2020 Aug 27.
How much difference there is between hepatic resection (HR) combined with intraoperative radiofrequency ablation (RFA) and living donor liver transplantation (LDLT) in treatment of multifocal hepatocellular carcinomas (HCCs) remains unclear. This study compared outcomes for patients with multifocal HCCs meeting the University of California San Francisco (UCSF) criteria treated by LDLT or HR + RFA.
A total of 126 consecutive Child-Pugh A patients with multifocal HCCs meeting the UCSF criteria, who underwent LDLT (n = 51) or HR + RFA (n = 75), were included. Propensity score (PS) matching was performed to adjust for baseline differences. Overall survival (OS) and recurrence-free survival (RFS) were calculated, and subgroup, multivariate and nomogram analyses were performed.
LDLT provided significantly better OS and RFS than did HR + RFA before and after PS matching and reduced the dropout rate on waiting list, but HR + RFA was more convenient, less invasive and less cost. Patients with all lesions located in the same lobe had better OS and RFS than those located in the different lobes after HR + RFA. Multivariate and nomogram analyses revealed that HR + RFA, alpha-fetoprotein ≥ 400 ng/mL, the major tumour size > 3 cm and microvascular invasion were independent predictors of poor prognosis.
For Child-Pugh A patients with multiple HCCs meeting the UCSF criteria, LDLT may offer significantly better long-term results than did HR + RFA, and HR + RFA may still be considered as an acceptable curative therapy for those without considering transplantation or as a bridge treatment for a patient, with a plan for transplantation in the future.
肝切除术(HR)联合术中射频消融(RFA)与活体肝移植(LDLT)治疗多灶性肝细胞癌(HCC)的疗效差异尚不清楚。本研究比较了符合加利福尼亚大学旧金山分校(UCSF)标准的多灶性 HCC 患者接受 LDLT 或 HR+RFA 治疗的结果。
共纳入 126 例符合 UCSF 标准的 Child-Pugh A 级多灶性 HCC 患者,接受 LDLT(n=51)或 HR+RFA(n=75)治疗。采用倾向评分(PS)匹配来调整基线差异。计算总生存期(OS)和无复发生存期(RFS),并进行亚组、多变量和列线图分析。
PS 匹配前后,LDLT 组的 OS 和 RFS 明显优于 HR+RFA 组,且降低了等待名单上的脱落率,但 HR+RFA 更方便、创伤更小、费用更低。HR+RFA 治疗后,所有肿瘤位于同一肝叶的患者 OS 和 RFS 优于肿瘤位于不同肝叶的患者。多变量和列线图分析显示,HR+RFA、甲胎蛋白(AFP)≥400ng/ml、肿瘤最大径>3cm 和微血管侵犯是预后不良的独立预测因素。
对于符合 UCSF 标准的多灶性 HCC 且 Child-Pugh A 级的患者,LDLT 可能比 HR+RFA 提供更好的长期结果,对于不考虑移植或计划未来移植的患者,HR+RFA 仍可作为一种可接受的根治性治疗方法,或作为一种桥接治疗方法。